After the Indian drug regulator turned down Dr. Reddy’s Laboratories Ltd’s proposal earlier this month to conduct direct Phase-3 human trials for the Russian Covid-19 vaccine Sputnik V, the company and Russia’s sovereign wealth fund Russian Direct Investment Fund (RDIF) have now received the Drug Control General of India (DCGI) nod to conduct an adaptive Phase 2/3 human clinical trial for the Russian vaccine in India.
Read more here:: India News Times